Several of these compounds have progressed to clinical evaluation, known for their potency and selectivity as a GlyT1 inhibitor, progressed to phase II clinical trials, particularly focusing on schizophrenia aimed at assessing their efficacy as an adjunctive therapy for negative symptoms in schizophrenic patients receiving concurrent antipsychotic treatment, but these trials were discontinued several years ago due to unspecified safety concerns (Javitt et al
However, advancements in drug delivery systems, including nanoparticles and liposomes, offer potential solutions to these limitations (Nabi, Arain, Hassan, et al
Also: if your goal is better body composition on a GLP-1, the most evidence-based stack is not another peptideits protein targets, resistance training, sleep, and careful dose/titration strategy
Mithieux G